Why Trimi Offers 3 GLP-1 Medications: The Power of Choice
One size does not fit all in medicine. Trimi is one of the few providers offering semaglutide, tirzepatide, and retatrutide because your body deserves the right medication, not the only medication your provider carries.
Most GLP-1 telehealth providers offer one medication, maybe two. Trimi offers three: compounded semaglutide ($99/mo), compounded tirzepatide ($125/mo), and retatrutide. This is not about having a bigger menu. It is about giving your medical provider the tools to find the right fit for your unique biology.
Medical Disclaimer
This article is informational. Your Trimi provider will recommend the most appropriate medication based on your individual medical evaluation.
The Three Medications Compared
Side-by-Side Comparison
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor targets | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Avg weight loss | 15-17% | 20-25% | Up to 24%+ (early data) |
| Trimi price | $125/mo | $125/mo | Contact |
| Clinical data | Extensive (STEP trials) | Extensive (SURMOUNT) | Phase 2 completed |
| Best for | Proven results, budget | Maximum weight loss | Next-gen approach |
Why Choice Matters in GLP-1 Treatment
Every patient's biology is different. Genetic variations affect how your body metabolizes GLP-1 medications. Side effect profiles differ between medications, and what is intolerable for one patient is barely noticeable for another. Efficacy varies based on individual receptor sensitivity. And comorbid conditions may make one medication more appropriate than another.
When a provider only offers semaglutide, your options when it does not work well are limited: increase the dose (which increases side effects) or stop treatment. When a provider offers three medications, your provider can switch you to an alternative that may work better for your body. This flexibility dramatically improves the odds of finding your optimal treatment.
Semaglutide: The Proven Performer
Semaglutide is the most extensively studied GLP-1 medication for weight loss. The STEP clinical trial program demonstrated average weight loss of 15 to 17 percent of body weight over 68 weeks. It has years of real-world safety data, well-understood side effect profiles, and established dosing protocols. At $99/mo from Trimi, it is also the most affordable option, making it an excellent starting point for many patients.
Tirzepatide: The Dual-Action Powerhouse
Tirzepatide targets both GLP-1 and GIP receptors, producing greater average weight loss (20 to 25 percent body weight) than semaglutide alone. The SURMOUNT trials showed that some patients lost over 50 pounds. The dual mechanism may also provide superior blood sugar control and cardiovascular benefits. At $125/mo, it offers more weight loss per dollar despite the higher monthly cost.
Retatrutide: The Next Frontier
Retatrutide adds a third target, the glucagon receptor, to the GLP-1 and GIP agonism of tirzepatide. Phase 2 clinical trial results published in the New England Journal of Medicine showed weight loss of up to 24 percent at 48 weeks, with some patients losing even more. The glucagon receptor component may provide additional metabolic benefits including improved liver health and enhanced fat oxidation.
How Your Provider Helps You Choose
Selection Factors
- Health history: Existing conditions may favor one medication
- Weight loss goals: Higher goals may benefit from dual or triple agonists
- Budget: Semaglutide at $99/mo is the most affordable starting point
- Side effect tolerance: Prior GLP-1 experience informs selection
- Metabolic profile: Diabetes, insulin resistance, and liver health considerations
The Bottom Line
Having three GLP-1 medication options is not a marketing gimmick. It is a clinical advantage that increases your probability of finding the right treatment for your body. Trimi's commitment to offering semaglutide, tirzepatide, and retatrutide reflects a patient-first approach: your biology should determine your medication, not your provider's limited inventory.
Find Your Right GLP-1 with Trimi
Three medications. One provider. Semaglutide $99/mo, tirzepatide $125/mo, retatrutide available.
Explore OptionsMore on trimi
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).